Skip to main content
. Author manuscript; available in PMC: 2015 Apr 8.
Published in final edited form as: Gerontology. 2014 Apr 8;60(5):381–385. doi: 10.1159/000358875

Table II.

Clinical Trials

Approach Mechanism of action references
Tideglusib Inhibitor of GSK 3β (in Phase IIb)
Completed but results not yet reported		 [16]
TauRx Inhibits tau aggregation (in Phase II) [12]
LMTX Reduces the level of aggregated and misfolded tau (in Phase III) [12]
AADvac1 Peptide targeting pathological tau (in Phase I) Clinicaltrials.gov